Exelixis EXEL
NASDAQ EXEL
$59.02 -0.11 (-0.19%)
As of: Sep 4, 2026 · 3:59 PM EDT

Exelixis (EXEL) Cash from Investing Activities (2010 - 2026)

Exelixis (EXEL) posted quarterly Cash from Investing Activities of -$51.1 million for Q2 2026, down 202.62% year-over-year from $49.8 million in Q2 2025, and down 287.47% quarter-over-quarter from $27.2 million in Q1 2026.

Analysis

Exelixis (EXEL) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Exelixis' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$51.1 million for Q2 2026.

  • In Q2 2026, Cash from Investing Activities fell 202.62% year-over-year to -$51.1 million; the TTM figure through Apr 2026 stood at $249.6 million (up 239.59% YoY), while the FY2026 annual figure was $350.4 million, up 400.08% from the prior year.
  • Cash from Investing Activities for Q2 2026 stood at -$51.1 million, down from $27.2 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $248.0 million in Q3 2025, with the low at -$245.8 million in Q4 2022.
  • The 5-year median for Cash from Investing Activities is -$49.6 million (2023), against an average of -$21.7 million.
  • The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities slumped 1782.67% in 2022, then soared 325.43% in 2024.
  • Exelixis' Cash from Investing Activities stood at -$245.8 million in 2022, then jumped by 125.12% to $61.7 million in 2023, then slumped by 451.73% to -$217.1 million in 2024, then soared by 111.7% to $25.4 million in 2025, then slumped by 301.02% to -$51.1 million in 2026.
  • Business Quant data shows EXEL's Cash from Investing Activities at -$51.1 million in Q2 2026, $27.2 million in Q1 2026, and $25.4 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -45.80 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -92.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 329.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -1.66 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -49.35 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -363.46 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -229.72 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 24.51 Mn
10 Exelixis 14.81 Bn 13.97 Bn 608.03 Mn 91.43 Mn
Historic Data

Historic Data

Download Data
DateValue
Jul 3, 2026 91.43 Mn
Apr 3, 2026 -51.07 Mn
Jan 2, 2026 27.24 Mn
Oct 3, 2025 25.41 Mn
Jul 4, 2025 248.03 Mn
Apr 4, 2025 49.76 Mn
Jan 3, 2025 -93.20 Mn
Sep 27, 2024 -217.15 Mn
Jun 28, 2024 81.77 Mn
Mar 29, 2024 111.79 Mn
Dec 29, 2023 61.74 Mn
Sep 29, 2023 34.69 Mn
Jun 30, 2023 -73.79 Mn
Mar 31, 2023 -49.59 Mn
Dec 30, 2022 -245.78 Mn
Sep 30, 2022 -68.95 Mn
Jul 1, 2022 -135.14 Mn
Apr 1, 2022 -74.54 Mn
Dec 31, 2021 -13.06 Mn
Oct 1, 2021 -21.24 Mn